𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase II study of subcutaneously administered 5-azacytidine (NSC-102816) in patients with metastatic malignant melanoma

✍ Scribed by Bellet, Robert E. ;Catalano, R. B. ;Mastrangelo, Michael J. ;Berd, David

Publisher
John Wiley and Sons
Year
1978
Tongue
English
Weight
268 KB
Volume
4
Category
Article
ISSN
0098-1532

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Thirty (30) patients with advanced metastatic malignant melanoma refractory to DTIC (NSC‐45388) and a nitrosourea were treated with 5‐azacytidine (NSC‐102816). 5‐Azacytidine was administered subcutaneously at a dosage of 100 mg/m^2^/day for 10 days. Twenty‐six (26) patients were evaluable for toxicity and response. Major organ toxicities were hematologic, gastrointestinal, and cutaneous; no antitumor activity was noted.

πŸ“œ SIMILAR VOLUMES

Phase II study of high-dose tamoxifen (N
Phase II study of high-dose tamoxifen (NSC-180973) in patients with disseminated malignant melanoma
✍ Edward T. Creagan; James N. Ingle; David L. Ahmann; Stephanie J. Green πŸ“‚ Article πŸ“… 1982 πŸ› John Wiley and Sons 🌐 English βš– 206 KB πŸ‘ 3 views

Seventeen patients with disseminated malignant melanoma received a daily oral regimen of tamoxifen, 100 mg/m2. All patients had prior chemotherapy and predominantly visceral involvement. None of the patients had an objective regression and most (71%) had progressive disease at the time of first reas

Phase II trial of subcutaneously adminis
Phase II trial of subcutaneously administered granulocyte-macrophage colony-stimulating factor in patients with metastatic renal cell carcinoma
✍ Edward Wos; Thomas Olencki; Laurie Tuason; G. Thomas Budd; David Peereboom; Kate πŸ“‚ Article πŸ“… 1996 πŸ› John Wiley and Sons 🌐 English βš– 465 KB πŸ‘ 2 views

## BACKGROUND. Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a cytokine that is involved in the differentiation and proliferation of various hematopoietic precursors. It also has been reported to enhance the antitumor activity of various mature effector cells. Previous reports have

A phase II study of autologous irradiate
A phase II study of autologous irradiated tumor cells plus BCG in patients with metastatic malignant melanoma
✍ J. Frederick Laucius; Audley J. Bodurtha; Michael J. Mastrangelo; Robert E. Bell πŸ“‚ Article πŸ“… 1977 πŸ› John Wiley and Sons 🌐 English βš– 285 KB πŸ‘ 2 views

Eighteen patients with surgically incurable metastatic malignant melanoma were treated with a mixture of irradiated (15,000 rads) autologous tumors cells (1-2 X 10(8)) and BCG (Glaxo, 2-4.5 X 10(6) organisms), which was injected intradermally (in five divided doses) every 2 weeks (X5). Four of 18 (2